Helius Medical Tech Stock (HSDT) Surges 100% on Aetna Coverage News

Helius Medical Technologies saw its stock price double in pre-market trading after securing an authorized claim for payment from CVS Health''s Aetna unit. The neurotech company''s Portable Neuromodulation Stimulator (PoNS) device gained its third major healthcare coverage agreement, marking a potential turnaround for the struggling stock.

CEO Dane Andreeff emphasized ongoing efforts to expand in-network coverage with commercial payers while maintaining case-by-case reimbursement negotiations. The 98.82% pre-market surge contrasts sharply with the stock''s 91.5% year-to-date decline prior to the announcement.

Wall Street remains cautious, with TipRanks'' AI analyst Spark maintaining an Underperform rating and $1 price target. The algorithm cites persistent financial and operational hurdles despite the recent coverage win.